Plain-English translation of NCT06665815 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This is a screening program for family members of people with type 1 diabetes. Researchers will take a blood sample to look for special markers called islet autoantibodies that can show if your body is starting to develop type 1 diabetes before you have any symptoms. If these markers are found, you'll get education and monitoring to help prevent complications.
Type 1 diabetes can develop quickly and cause a dangerous condition called diabetic ketoacidosis (DKA). By catching early signs of diabetes in family members before symptoms appear, doctors hope to prevent serious complications and help people stay healthy.
You likely qualify if…
You likely don't qualify if…
You will have a blood sample taken to test for autoantibodies. If your first test shows two or more markers, you'll be asked to provide a second blood sample to confirm the results. If confirmed as having early-stage diabetes, you'll receive education focused on preventing dangerous complications and regular follow-up care as part of your routine medical care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Israel
Enrollment target
~20,000 participants
Started
December 2024
Primary completion
December 2027
Age range
2 Years – 45 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Moshe Phillip, Prof.
Schneider Children's Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.